PrintThe Burrill Report
The Burrill Report (March 28, 2011): Why Big Pharma's Got Executive Compensation All Wrong (.MP3,13.57 Mb)
Over the past decade large pharmaceutical companies have experienced an enormous loss of value. But as the pressure increases to introduce innovative new products to replace revenue being lost to competition from generic drugs, corporate boards have done little to alter executive compensation away from traditional financial metrics to new incentives that align compensation with the ultimate drivers of a pharmaceutical company’s business. We spoke to Matt Gurin, vice president and life sciences specialist at the management consulting firm Hay Group, about Big Pharma’s approach to executive compensation, why it’s not working, and what these companies could learn from smaller biotechs.
March 25, 2011
http://www.burrillreport.com/article-why_big_pharmas_got_executive_compensation_all_wrong_.html
EXECUTIVE COMPENSATION
Why Big Pharma's Got Executive Compensation All Wrong
Podcast: March 28, 2011[Please login to post comments]
- BioConference Live Interview with G. Steven Burrill
A discussion about Biotech 2011-Life Sciences: Looking Back to See Ahead Read More - California Joins Whistleblower Lawsuit against BMS over Alleged Kickbacks to Docs
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - U.S. and Brazil Expand Agreement to Include Aviation Biofuels
Brazillian industry group calls development an encouraging step toward the end of tariff that keeps corn-derived ethanol competitive with sugar-cane derived fuel. Read More - NIH Announces New Strategic Plan to Combat Diabetes
Stakeholders tapped to develop roadmap for preventing, treating and finding a cure. Read More - Religious Groups Tell Pharma to Reel in Prices
Shareholder activists call on companies to tie pricing increases to inflation. Read More - Uncovering Healthcare’s Hidden Costs
A year after reform becomes law, study finds consumers spend billions not captured in government reporting. Read More - Cephalon Beefs Up its Cancer Pipeline
Acquisition of Gemin X will add experimental treatment for lung cancer. Read More - Procter & Gamble and Teva Forming OTC Drug Venture
Companies seek growth from emerging markets, brand recognition. Read More - BMS Wins FDA Approval for Melanoma Drug
Treatment is first shown to extend life for people with deadliest form of skin cancer. Read More - Gene Therapy Shows Promise in Treating Parkinson’s Disease
Neurologix’ novel drug improves patients’ symptoms in mid-stage study. Read More
.gif)
- Protalix Plans Human Clinical Tests of Medication for Rare Fabry's Disease
Bloomberg - Branded drug prices soar as generic pressure rises
Reuters - China to ban smoking at indoor public places
Reuters - A Panel Decides Washington State’s Health Care Costs
The New York Times - Supreme Court Rules Against Zicam Maker
The New York Times - Anxiety Over Radiation Drives a Sales Surge for a Drug Against Thyroid Cancer
The New York Times - HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success
Bloomberg - Alzheimer's drug hits two forms of toxic protein
Reuters - Number of Survivors of Cancer Rises 20 Percent
The New York Times - Mexico Puts Its Children on a Diet
The New York Times